The clinical study of initial induced remission failure in elderly patients with acute myeloid leukemia treated by HCAG/IA in combination with decitabine

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006896

Enrollment

Unknown

Registered

2015-07-30

Start date

2015-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukima

Interventions

Group A:D-IA

Group B:D-HCAG

Eligibility

Sex/Gender

All

Age

61 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. ALL candidates for this trial should first be participants in the "Homoharringtonine+CAG regimen for newly diagnosed elderly AML induction" trial; 2. Patients who resulted in Non-remission after the first induction can be included in this trial; 3. All patients will be evaluated by the researchers to see if they are qualified for this trial.

Exclusion criteria

Exclusion criteria: 1. Patients with ejection fraction =2.

Design outcomes

Primary

Measure	Time frame
Complete Remission Rate;Partial Remission Rate;Overall Survival;Progression Free Survival;Relapse Free Survival;	—

Countries

China

Contacts

Public ContactLI JUNMIN

lijunmin@medmail.com.cn+86 021-64370045-665258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026